王海天,王兰桂

脑梗死是脑部血液循环障碍，缺血缺氧所致的局限性脑组织的缺血性坏死或软化，是脑血管病最常见的类型。脑梗死是第三大残疾合并死亡原因的疾病，目前脑梗死的预后不太乐观，因此寻找新的治疗方案极为迫切。最新研究表明芬戈莫德对脑梗死具有神经保护作用。本文现围绕芬戈莫德对脑梗死通过不同的机制来发挥神经保护等方面做一综述。

芬戈莫德；脑梗死；缺血性脑卒中

[1] 周逸华,刘学润,郭名君,等.髓过氧化物酶与脑卒中关系的研究进展[J].中华医学杂志,2022,21(12):1290-1296. [2] Kisa A,Kisa S,Collaborators GS.Global,regional,and national burden of stroke and its risk factors,1990–2019:a systematic analysis for the Global Burden of Disease Study 2019[J].The Lancet Neurology,2021:26. [3] 中国卒中学会,中国卒中学会神经介入分会,中华预防医学会卒中预防与控制专业委员会介入学组,等.急性缺血性卒中血管内治疗中国指南2023[J].中国卒中杂志,2023,18(6):684-711. [4] Zhu XY,Ma TT,Li Y,et al.Fingolimod protects against neurovascular unit injury in a rat model of focal cerebral ischemia/reperfusion injury[J].Neural Regen Res,2023,18(4):869-874. [5] Chiba K.Discovery of fingolimod based on the chemical modification of a natural product from the fungus,Isaria sinclairii[J].J Antibiot (Tokyo),2020,73(10):666-678. [6] Chun J,Giovannoni G,Hunter S F.Sphingosine 1-phosphate Receptor Modulator Therapy for Multiple Sclerosis:Differential Downstream Receptor Signalling and Clinical Profile Effects[J].Drugs,2020(15). [7] Groves A,Kihara Y,Chun J.Fingolimod:direct CNS effects of sphingosine 1-phosphate(S1P)receptor modulation and implications in multiple sclerosis therapy[J].J Neurol Sci,2013,328(1-2):9-18. [8] Nitzsche A,Poittevin M,Benarab A,et al.Endothelial S1P1 Signaling Counteracts Infarct Expansion in Ischemic Stroke[J].Circ Res,2021,128(3):363-382. [9] Jęśko H,Wencel PL,Lukiw WJ,et al.Modulatory Effects of Fingolimod(FTY720)on the Expression of Sphingolipid Metabolism-Related Genes in an Animal Model of Alzheimer's Disease[J].Mol Neurobiol,2018. [10] Lei T,Yang Z,Jiang C,et al.Mannose-Integrated Nanoparticle Hitchhike Glucose Transporter 1 Recycling to Overcome Various Barriers of Oral Delivery for Alzheimer's Disease Therapy[J].ACS Nano.2024,18(4):3234-3250. [11] Williams GP,Schonhoff AM,Jurkuvenaite A,Gallups NJ,Standaert DG,Harms AS.CD4 T cells mediate brain inflammation and neurodegeneration in a mouse model of Parkinson's disease.Brain.2021,144(7):2047-2059. [12] Barthels D,Das H.Current advances in ischemic stroke research and therapies[J].BBA,2020(4). [13] Pournajaf S,Dargahi L,Javan M,et al.Molecular Pharmacology and Novel Potential Therapeutic Applications of Fingolimod[J]. Frontiers in pharmacology,2022,13:807639. [14] Zhang W,Li Y,Li F,et al.Sphingosine-1-phosphate receptor modulators in stroke treatment[J].J Neurochem,2022,162(5):390-403. [15] Malone K,Diaz ACD,Shearer J A,et al.The effect of fingolimod on regulatory T cells in a mouse model of brain ischaemia[J].Journal of Neuroinflammation,2021(1). [16] Wang M,Thomson AW,Yu F,Hazra R,Junagade A,Hu X.Regulatory T lymphocytes as a therapy for ischemic stroke.Semin Immunopathol.2023;4 [17] Ito M,Komai K,Mise-Omata S,et al.Brain regulatory T cells suppress astrogliosis and potentiate neurological recovery.Nature. 2019; 565(7738):246-250. [18] Wang Z,Kawabori M,Houkin K.FTY720(Fingolimod)Ameliorates Brain Injury through Multiple Mechanisms and is a Strong Candidate for Stroke Treatment[J].Curr Med Chem,2020. [19] Naseh M,Vatanparast J,Rafati A,et al.The emerging role of FTY720 as a sphingosine 1‐phosphate analog for the treatment of ischemic stroke:The cellular and molecular mechanisms[J].Brain Behav,2021,11(6):e02179. [20] Li YJ,Shi SX,Liu Q,et al.Targeted role for sphingosine-1-phosphate receptor 1 in cerebrovascular integrity and inflammation during acute ischemic stroke[J].Neurosci Lett,2020,735:135160. [21] Wei Y,Yemisci M,Kim HH,et al.Fingolimod provides long-term protection in rodent models of cerebral ischemia[J].Ann Neurol, 2011,69(1):119-129. [22] Masahiko I,Satoru I,Fuying L,et al.Sphingosine-1-Phosphate Receptor-1 Selective Agonist Enhances Collateral Growth and Protects against Subsequent Stroke[J].Plos One,2015,10(9):e0138029. [23] Sweeney MD,Zhao Z,Montagne A,et al.Blood-Brain Barrier:From Physiology to Disease and Back[J].Physiol Rev,2019,99(1):21-78. [24] Brown RC,Davis TP.Calcium modulation of adherens and tight junction function:a potential mechanism for blood-brain barrier disruption after stroke[J].Stroke,2002,33(6):1706. [25] Hawkins BT,Davis TP.The blood-brain barrier/neurovascular unit in health and disease[J].Physiol Rev,2005,57(2):173-85. [26] Candelario-Jalil E,Dijkhuizen RM,Magnus T.Neuroinflammation,Stroke,Blood-Brain Barrier Dysfunction,and Imaging Modalities[J]. Stroke,2022,53(5):1473-1486. [27] Miron E,Schubart A,Antel JP.Central nervous system-directed effects of FTY720(fingolimod)[J].J Neurol Sci,2008,274(1-2):13-17. [28] Wang Z,Higashikawa K,Yasui H,et al.FTY720 Protects Against Ischemia-Reperfusion Injury by Preventing the Redistribution of Tight Junction Proteins and Decreases Inflammation in the Subacute Phase in an Experimental Stroke Model[J].Transl Stroke Res, 2020,11(5):1103-1116. [29] Cannon RE,Peart JC,Hawkins BT,et al.Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain[J].Proc Natl Acad Sci USA,2012,109(39):15930-15935. [30] Lee JF,Zeng Q,Ozaki H,et al.Dual Roles of Tight Junction-associated Protein,Zonula Occludens-1,in Sphingosine 1-Phosphate- mediated Endothelial Chemotaxis and Barrier Integrity[J].J Biol Chem,2006,281(39):29190-200 [31] Spampinato SF,Obermeier B,Cotleur A,et al.Sphingosine 1 Phosphate at the Blood Brain Barrier:Can the Modulation of S1P Receptor 1 Influence the Response of Endothelial Cells and Astrocytes to Inflammatory Stimuli?[J].Plos One,2015,10(7):e0133392. [32] Cai A,Schlunk F,Bohmann F,et al.Coadministration of FTY720 and rt-PA in an experimental model of large hemispheric stroke–no influence on functional outcome and blood–brain barrier disruption[J].Exp Transl Stroke Med,2013,5(1):11. [33] Safarian F,Khallaghi B,Ahmadiani A,et al.Activation of S1P receptor regulates PI3K/Akt/FoxO3a pathway in response to oxidative stress in PC12 cells[J].J Mol Neurosci,2015,56(1):177-87. [34] Xiao L,Ming-Huan W,Chuan Q,et al.Fingolimod suppresses neuronal autophagy through the mTOR/p70S6K pathway and alleviates ischemic brain damage in mice[J].Plos One,2017,12(11):e0188748. [35] Hasegawa Y,Suzuki H,Sozen T,et al.Activation of sphingosine 1-phosphate receptor-1 by FTY720 is neuroprotective after ischemic stroke in rats[J].Stroke,2010,41(2):368. [36] Wen YD,Sheng R,Zhang LS,et al.Neuronal injury in rat model of permanent focal cerebral ischemia is associated with activation of autophagic and lysosomal pathways[J].Autophagy,2008,4(6):762-769. [37] Li X,Wang MH,Qin C,et al.Fingolimod suppresses neuronal autophagy through the mTOR/p70S6K pathway and alleviates ischemic brain damage in mice[J].PLoS One,207,e0188748. [38] Chen GZ,Shan XY,Li XS,et al.Remote ischemic postconditioning protects the brain from focal ischemia/reperfusion injury by inhibiting autophagy through the mTOR/p70S6K pathway[J].Neurol Res,2018,40(3):1. [39] Limaye V,Li X,Hahn C,et al.Sphingosine kinase-1 enhances endothelial cell survival through a PECAM-1–dependent activation of PI-3K/Akt and regulation of Bcl-2 family members[J].Blood,2005,105(8):3169-3177. [40] Tian DC,Shi K,Zhu Z,et al.Fingolimod Enhances the Efficacy of Delayed Alteplase Administration in Acute Ischemic Stroke by Promoting Anterograde Reperfusion and Retrograde Collateral Flow:Fingolimod and tPA in AIS[J].Ann Neurol,2018,84. [41] Zhu Z,Fu Y,Tian D,et al.Combination of the Immune Modulator Fingolimod With Alteplase in Acute Ischemic Stroke:A Pilot Trial[J].Circulation,2015,132(12). [42] Fu Y,Zhang N,Ren L,et al.Impact of an immune modulator fingolimod on acute ischemic stroke[J].Proc Natl Acad Sci USA, 2014,111(51):18315.

点击下载PDF